Drug Trial Radar · NCT07234474
A Phase I Study of YK012 in Primary Membranous Nephropathy
Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
66
Planned (sponsor's estimate)
Start
Sep 2027
Primary completion
Oct 2028
Study completion Jan 2029
Sponsor
- Lead sponsor
- Excyte Biopharma LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics(PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of YK012 in participants with primary membranous nephropathy (pMN).
Conditions
- Primary Membranous Nephropathy
Interventions
YK012Drug
YK012 is a bispecific antibody targeting CD19 on B cells and CD3 on T cells leading to T cell-mediated cytotoxicity of malignant B cells
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ia: Dose-Limiting Toxicity (DLT)Time frame: up to 28 days after the first dose
- Adverse Event (AE)Time frame: From the first induction to the end of the trial at 53 weeks
- Severe Adverse EventTime frame: From the first induction to the end of the trial at 53 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.